Nicox's Glaucoma Drug NCX 470 Gains FDA Green Light for 2026 Submission

SOPHIA ANTIPOLIS, France – February 16, 2026 – French ophthalmology firm Nicox SA has cleared a significant regulatory hurdle for its promising glaucoma treatment, NCX 470, after receiving positive feedback from the U.S. Food and Drug Administration (FDA). The written response from a pre-New Drug Application (NDA) meeting confirms that the company's comprehensive data package is on the right track for a U.S. filing, keeping the submission timeline firmly set for summer 2026.

This development is a crucial step forward for the novel eye drop, designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The positive FDA correspondence significantly de-risks the path to market in the lucrative U.S. ophthalmology space and validates the strength of the drug's late-stage clinical results.

A Clearer Path in a Crowded Market

The feedback from the FDA confirms that the existing clinical data, along with the proposed content and format for the NDA, are "generally acceptable for submission." This endorsement from the agency provides Nicox and its global partner, Kowa, a clear runway for finalizing the registration dossier.

"The productive and collaborative pre-NDA meeting with the FDA was conducted with our partner Kowa," said Doug Hubatsch, EVP and Chief Scientific Officer of Nicox, in a company statement. "The outcome supports the finalisation of our registration dossier with its comprehensive data package, including positive results from two Phase 3 studies, and facilitates proceeding with submitting the NCX 470 New Drug Application to the U.S. Food and Drug Administration."

Following this milestone, Nicox will transfer ownership of the application to Kowa, which will spearhead the U.S. submission. This move triggers a forthcoming milestone payment to Nicox, reinforcing the company's partnership-centric business model.

The market NCX 470 aims to enter is substantial. The global glaucoma treatment market was valued at over $7 billion in 2022 and is projected to exceed $12 billion by 2032, with the U.S. accounting for a major share. Despite a range of available therapies, significant unmet needs persist. Many patients require multiple medications to control their IOP, and issues with side effects often lead to poor adherence. The medical community continues to seek more potent, well-tolerated, and convenient once-daily treatments that can effectively manage this chronic, vision-threatening disease.

The Science of Superior Pressure Reduction

NCX 470, chemically known as bimatoprost grenod, stands out due to its innovative dual mechanism of action. It combines the proven IOP-lowering power of bimatoprost—a widely used prostaglandin analog—with a novel nitric oxide (NO)-donating component. This dual-action design targets two distinct pathways to increase the outflow of aqueous humor from the eye. While bimatoprost primarily enhances uveoscleral outflow, the released nitric oxide helps relax the trabecular meshwork, improving the conventional outflow pathway.

This scientific approach has been validated in a robust Phase 3 clinical program. The NDA submission will be anchored by data from two pivotal studies, Mont Blanc and Denali, which demonstrated NCX 470's superior efficacy. In these trials, the drug achieved statistically significant and clinically meaningful reductions in IOP, lowering pressure by up to 10 mmHg.

Crucially, NCX 470 proved superior to some of the market's most established treatments. The Denali study showed that NCX 470 provided a greater IOP reduction than bimatoprost 0.03% (marketed as Lumigan), a current standard of care. This head-to-head superiority could position NCX 470 as a powerful new first-line or step-up therapy for patients who are not achieving their target IOP with existing medications. While the drug was generally well-tolerated, its most common side effect was conjunctival hyperemia (eye redness), an effect common to the prostaglandin class of drugs.

This is not Nicox's first foray into nitric oxide-donating compounds. Its first product, VYZULTA (latanoprostene bunod), which is licensed to Bausch + Lomb, also utilizes an NO-donating mechanism and is already available in the U.S. NCX 470 can be seen as a next-generation asset in this platform, pairing the NO-donating technology with bimatoprost, a more potent prostaglandin than VYZULTA's latanoprost.

A Global Strategy Fueled by Partnerships

The advancement of NCX 470 showcases Nicox's lean, partnership-driven business strategy. Rather than bearing the immense cost of global commercialization, the company focuses on research and development before out-licensing its assets to partners with established commercial infrastructure and regional expertise.

For NCX 470, Nicox has secured two major partnerships. Kowa Company, Ltd., a Japanese multinational, holds the rights to develop and commercialize the drug in the U.S., Japan, and other key territories. Under the terms of their expanded agreement, Nicox is eligible for up to $185 million in milestone payments, plus tiered royalties on net sales ranging from 8% to 15%. The upcoming NDA submission by Kowa will trigger one such milestone payment, providing a welcome infusion of non-dilutive capital.

In the rapidly growing Asian markets, Nicox has partnered with Ocumension Therapeutics. This agreement covers the commercialization of NCX 470 in China, South Korea, and Southeast Asia, with Nicox set to receive up to $45 million in milestones and royalties of 5% to 9%. These strategic alliances allow Nicox to maintain a global footprint for its lead asset while mitigating financial risk and focusing its resources on its development pipeline.

Navigating the Final Regulatory Hurdles

With the pre-NDA meeting concluded, the path forward is clearly defined. The U.S. submission is slated for summer 2026, with an NDA submission in China expected to follow shortly after. The FDA did request complementary pharmacokinetic data, but Nicox has stated this will not impact timelines as the necessary information will be generated from a small number of patients in an ongoing Phase 3 study in Japan.

Once the NDA is submitted to the FDA, a standard review process typically takes ten months, though a Priority Review could shorten this to six months. Given the drug's superior efficacy data, a Priority Review designation could be a possibility, potentially accelerating its availability to patients. The positive feedback from the pre-NDA meeting suggests that the application is well-prepared, minimizing the risk of a "Refuse to File" decision or significant delays during the review cycle.

The successful navigation of this key regulatory milestone brings NCX 470 one step closer to becoming a new, powerful tool for ophthalmologists. For the millions of people living with glaucoma, the potential arrival of a more effective treatment offers renewed hope in the ongoing fight to preserve sight.